FilingReader Intelligence
Glenmark's Ichnos inks exclusive licensing deal with AbbVie
July 10, 2025 at 11:29 AM UTC•By FilingReader AI
Glenmark Pharmaceuticals has announced that its step-down wholly-owned subsidiary, Ichnos Glenmark Innovation (IGI), has entered into an exclusive global licensing agreement with AbbVie for ISB 2001, a first-in-class CD38×BCMA×CD3 trispecific antibody currently in Phase 1 clinical trials for relapsed/refractory multiple myeloma (R/R MM).
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:GLENMARK•Bombay Stock Exchange
News Alerts
Get instant email alerts when Glenmark Pharmaceuticals publishes news
Free account required • Unsubscribe anytime